This invention relates generally to olefin metathesis catalysts, to the preparation of such compounds, compositions comprising such compounds, methods of using such compounds, and the use of such compounds in the metathesis of olefins and in the synthesis of related olefin metathesis catalysts. The invention has utility in the fields of catalysis, organic synthesis, polymer chemistry, and in industrial applications such as oil and gas, fine chemicals and pharmaceuticals.

The present disclosure provides, in some aspects, macromonomers of Formula (I), and salts thereof; methods of preparing the macromonomers, and salts thereof; Brush prodrugs (polymers); methods of preparing the Brush prodrugs; compounds of Formula (II); conjugates of Formula (III), and salts thereof; pharmaceutical compositions comprising a Brush prodrug, or a conjugate or a salt thereof; kits comprising: a macromonomer or a salt thereof, a Brush prodrug, a compound, a conjugate or a salt thereof, or a pharmaceutical composition; methods of using the Brush prodrugs, or conjugates or salts thereof; and uses of the Brush prodrugs, and conjugates or salts thereof. These chemical entities may be useful in delivering pharmaceutical agents to a subject or cell.

The present invention provides a ruthenium compound represented by the following general formula (1) or (2), a thin-film forming raw material containing the ruthenium compound, and a method of producing a thin-film including using the thin-film forming raw material:

##STR00001##

where R.sup.1 to R.sup.12 each independently represent a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, or a fluorine atom-containing group, and “n” represents an integer from 0 to 2, provided that at least one of R.sup.1 to R.sup.12 represents the fluorine atom-containing group;

##STR00002##

where R.sup.13 to R.sup.17 each independently represent a hydrogen atom or an alkyl group having 1 to 5 carbon atoms, and a total number of the carbon atoms of R.sup.11 to R.sup.17 is 3 or more.

Provided herein, in part, is a new class of sterically bulky, easily prepared N-heterocyclic carbene (NHC) ligands of Formula I, or a salt, solvate, geometric isomer, or stereoisomer thereof. The ligands are readily synthetically accessible exploiting the cost-effective, modular alkylation of anilines. The NHC ligands of the present disclosure can be used to prepare effective catalysts with transition metals, including the compound of Formula II, or a salt, solvate, geometric isomer, or stereoisomer thereof. In certain embodiments, the transition metal is Pd.

The present invention relates to a raw material of an organoruthenium compound for producing a ruthenium thin film or a ruthenium compound thin film by a chemical deposition method. This organoruthenium compound is an organoruthenium compound represented by the following Formula 1 and including a trimethylenemethane-based ligand (L.sub.1) and three carbonyl ligands coordinated to divalent ruthenium. In Formula 1, the trimethylenemethane-based ligand L.sub.1 is represented by the following Formula 2:

##STR00001## wherein a substituent R of the ligand L.sub.1 is hydrogen, or any one of an alkyl group, a cyclic alkyl group, an alkenyl group, an alkynyl group, and an amino group having a predetermined number of carbon atoms.

Disclosed herein are methods for synthesizing fatty olefin metathesis products of high Z-isomeric purity from olefin feedstocks of low Z-isomeric purity. The methods include contacting a contacting an olefin metathesis reaction partner, such as acylated alkenol or an alkenal acetal, with an internal olefin in the presence of a Z-selective metathesis catalyst to form the fatty olefin metathesis product. In various embodiments, the fatty olefin metathesis products are insect pheromones. Pheromone compositions and methods of using them are also described.

Disclosed herein are ruthenium arene Schiff-base complex and uses thereof. The ruthenium arene Schiff-base complex disclosed herein has the structure of formula (I),

##STR00001##

wherein, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11, and R.sub.12 are independently H, alkyl, alkoxyl, or halo; R.sub.13, R.sub.14, R.sub.15, R.sub.16, and R.sub.17 are independently H, alkyl, alkoxyl, hydroxy, halo, —C(═NH)NH.sub.2, —SO.sub.3H, —SO.sub.2NH.sub.2, —NR′R″, or —CONH.sub.2; or R.sub.13 and R.sub.14 are taken together to form a benzene ring, while R.sub.15, R.sub.16, and R.sub.17 are independently H, alkyl, alkoxyl, hydroxy, halo, —C(═NH)NH.sub.2, —SO.sub.3H, —SO.sub.2NH.sub.2, —NR′R″, or —CONH.sub.2; or R.sub.14 and R.sub.15 are taken together to form a benzene ring, while R.sub.13, R.sub.16, and R.sub.17 are independently H, alkyl, alkoxyl, hydroxy, halo, —C(═NH)NH.sub.2, —SO.sub.3H, —SO.sub.2NH.sub.2, —NR′R″, or —CONH.sub.2; R′ and R″ are independently H or alkyl; the alkyl is optionally substituted with one or more halo or hydroxy, or hydroxy; and Y is a counter anion. Also disclosed herein are methods of treating malignant neoplasm in a subject. The method includes administering an effective amount of the ruthenium arene Schiff-base complex of formula (I) to the subject to alleviate symptoms associated with the malignant neoplasm. Exemplary malignant neoplasm includes, but is not limited to triple-negative breast cancer.

Compound of formula 4 or formula 5 ##STR00001##
wherein
L is a neutral ligand, preferably a nitrogen-containing heterocyclic carbene (NHC) such as carbene containing at least two nitrogen atoms, a cyclic aminoalkyl carbene (CAAC) or a bicyclic aminoalkyl carbene (BICAAC);
R.sup.1, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10 and R.sup.11 are, independently, H, unbranched or branched C.sub.1-20 alkyl, C.sub.5-9 cycloalkyl, unbranched or branched C.sub.1-20 alkoxy, optionally bearing one or more halogen atoms, respectively; or aryl, optionally substituted with one or more of unbranched or branched C.sub.1-20 alkyl, C.sub.5-9 cycloalkyl, unbranched or branched C.sub.1-20 alkoxy, aryl, aryloxy, unbranched or branched C.sub.1-20 alkylcarbonyl, arylcarbonyl, unbranched or branched C.sub.1-20 alkoxycarbonyl, aryloxycarbonyl, heteroaryl, carboxyl, cyano, nitro, amido, aminosulfonyl, N-heteroarylsulfonyl, unbranched or branched C.sub.1-20 alkylsulfonyl, arylsulfonyl, unbranched or branched C.sub.1-20 alkylsulfinyl, arylsulfinyl, unbranched or branched C.sub.1-20 alkylthio, arylthio, sulfonamide, halogen or N(R.sup.y)(R.sup.z), wherein R.sup.y and R.sup.z are independently selected from H and C.sub.1-20 alkyl:
R.sup.2 is H, unbranched or branched C.sub.1-20 alkyl.

The disclosed and claimed subject matter relates to the ruthenium pyrazolate precursors and derivatives thereof as well as their uses in ALD or ALD-like processes and the films grown is such processes. In particular substituted unsaturated pyrazolate bridged diruthenium carbonyl complexes are disclosed.

The present invention relates to a novel ligand for forming a ruthenium complex, a ruthenium complex catalyst, a production method therefor and a use thereof. The ligand for forming a ruthenium complex and the ruthenium complex catalyst, according to the present invention, exhibit high catalytic activity, high selectivity, and stability.